December 10th & 11th, 2026
15th edition
MARSEILLE, FR

Kathrin Ladetzki-Baehs

Managing Director GT Protein Therapeutics
adivo GmbH – now part of Zoetis

Dr. Kathrin Ladetzki-Baehs began her career at MorphoSys, where she served in multiple roles within the R&D organization and ultimately as Director in Alliance Management, shepherding partnerships, and therapeutic projects in collaboration with international pharma partners. In 2018, she co-founded adivo GmbH, a MorphoSys spinout, alongside Dr. Markus Waldhuber, securing seed financing from High-Tech Gründerfonds, Occident and MorphoSys to develop CEASAR and FELIX, the first phage-display antibody libraries tailored for dogs and cats.

Scroll to Top

Before you leave…

Download the official BioFIT 2026 brochure

Discover the conference programme, partnership opportunities, attendee profiles, registration options and everything you need to make the most of BioFIT 2026.